Study assessing real life the efficacy of dual therapy (2DR) with JULUCA, and its effect on virological and immunological condition, lipid profile and inflammatory markers
Latest Information Update: 20 Dec 2022
At a glance
- Drugs Dolutegravir/rilpivirine (Primary)
- Indications HIV infections
- Focus Pharmacodynamics
Most Recent Events
- 20 Dec 2022 New trial record
- 26 Oct 2022 Results presented at the 16th International Congress on Drug Therapy and HIV Infection